MedTrace Logo

Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease

NCT02850978 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1335

Last updated 2019-12-06

Study results available
· View outcomes & findings →

Summary

Study to assess the long-term safety and effectiveness of Spiolto in Japanese patients with Chronic Obstructive Pulmonary Disease (COPD) in real-world setting

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Spiolto

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-23
Primary Completion
2018-10-30
Completion
2018-11-30

Countries

  • Japan

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02850978 on ClinicalTrials.gov